Leukemia
Advertisement
The approved dosing schedule for venetoclax is time-limited, but how many patients follow the schedule?
Though rare, CLL and CML sometimes occur sequentially or concurrently. But what is the mechanism behind the relationship?
In a currently enrolling trial, patients with CLL and NMSC will receive experimental treatment with nicotinamide.
Deborah Stephens, DO, presented the recommendations and algorithms for first-, second-, and third-line CLL/SLL therapy.
Adolescents and young adults face different challenges than older survivors of ALL. Can technology improve these challenges?
A recently approved TIW schedule provides new option for patients with ALL or LBL receiving asparaginase.
Interprofessional team-based care is the standard for patients undergoing HSCT. But who belongs on the team?
TKI resistance can cause challenges for patients with CML. New research seeks to identify biomarkers of early resistance.
A single-center study shows promising results using ponatinib and blinatumomab, including overall response rate.
These results indicate that nurses can lead exercise activity for ambulatory, alert, and oriented adult leukemia patients.
Researchers, led by Katharine McLaughlin, examined the relationship between changes in vital signs and admission to an ...
Researchers performed a meta-analysis to evaluate two hypomethylating agents (HMAs), decitabine and azacitidine, in the ...
Findings from a randomized trial, published in The Lancet Oncology, showed that combining enasidenib with azacitidine was ...
Researchers developed a method to measure standardized intracellular reactive oxygen species (siROS) levels in the CD34+ bone ...
In a systematic review and meta-analysis, researchers assessed the efficacy and safety of gemtuzumab ozogamicin (GO) in ...
In a case report published in the Journal of Oncology Pharmacy Practice, researchers described an incident of aplastic anemia ...
A study in Blood has found that nearly 14% of adult patients with acute myeloid leukemia (AML) have pathogenic or likely ...
Researchers analyzed baseline patient characteristics and first-line treatments on survival and CML–related mortality.
In a phase III study published in Blood, asciminib was associated with higher rates of major molecular response (MMR) than ...
Older patients with previously untreated acute myeloid leukemia (AML) who received oblimersen plus standard conventional ...
Advertisement
670 Madison Ave.
Manalapan, NJ 07726